Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of maralixibat for cholestatic pruritus
2024-511287-85-00Phase 3Authorised
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in cholestatic pruritus and cholestatic disease comparing Maralixibat with Placebo (2 arms). Primary endpoint: Change in average worst ItchRO(Obs) severity score. Planned start Feb 2025; status: authorised.
02
Drugs
maralixibat
03
Conditions
cholestatic prurituscholestatic disease
Beyond the preview
Go deeper on 2024-511287-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511287-85-00.